Nemaura Medical Analyst Ratings
Nemaura Medical Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
08/19/2022 | 268.66% | HC Wainwright & Co. | $12 → $8 | Maintains | Buy |
03/29/2022 | 453% | HC Wainwright & Co. | → $12 | Initiates Coverage On | → Buy |
12/02/2021 | 245.62% | EF Hutton | → $7.5 | Initiates Coverage On | → Buy |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
2022 年 8 月 19 日 | 268.66% | HC Wainwright & Co. | 12 美元 → 8 美元 | 维护 | 买 |
03/29/2022 | 453% | HC Wainwright & Co. | → 12 美元 | 启动覆盖范围开启 | → 购买 |
2021 年 2 月 12 日 | 245.62% | EF Hutton | → 7.5 美元 | 启动覆盖范围开启 | → 购买 |
Nemaura Medical Questions & Answers
Nemaura 医疗问题与解答
The latest price target for Nemaura Medical (NASDAQ: NMRD) was reported by HC Wainwright & Co. on August 19, 2022. The analyst firm set a price target for $8.00 expecting NMRD to rise to within 12 months (a possible 268.66% upside). 3 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2022年8月19日公布了内毛拉医疗(纳斯达克股票代码:NMRD)的最新目标股价。该分析公司将目标股价定为8.00美元,预计NMRD将在12个月内升至12个月内(可能上涨268.66%)。去年有3家分析公司公布了评级。
The latest analyst rating for Nemaura Medical (NASDAQ: NMRD) was provided by HC Wainwright & Co., and Nemaura Medical maintained their buy rating.
HC Wainwright & Co. 对Nemaura Medical(纳斯达克股票代码:NMRD)的最新分析师评级由HC Wainwright & Co. 提供,Nemaura Medical维持买入评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nemaura Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nemaura Medical was filed on August 19, 2022 so you should expect the next rating to be made available sometime around August 19, 2023.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与Nemaura Medical的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月做一次这样的评级,因此每家公司每年应该获得4次评级。Nemaura Medical的最新评级是在2022年8月19日公布的,因此您应该预计下一个评级将在2023年8月19日左右公布。
While ratings are subjective and will change, the latest Nemaura Medical (NMRD) rating was a maintained with a price target of $12.00 to $8.00. The current price Nemaura Medical (NMRD) is trading at is $2.17, which is out of the analyst's predicted range.
尽管评级是主观的,并且会发生变化,但最新的Nemaura Medical(NMRD)评级维持不变,目标股价为12.00美元至8.00美元。Nemaura Medical(NMRD)目前的交易价格为2.17美元,超出了分析师的预期区间。